Dextenza reduces signs of inflammatory dry eye in phase 2 exploratory trial

Dextenza showed promising results in a phase 2 exploratory clinical trial in the treatment of inflammatory dry eye disease, Ocular Therapeutix announced in a press release.The prospective, randomized, vehicle controlled phase 2 trial, conducted at two sites in the U.S., included 86 eyes of 43 patients.